Ernexa Therapeutics (ERNAW) Long-Term Debt Repayments (2014 - 2020)

Ernexa Therapeutics (ERNAW) has 7 years of Long-Term Debt Repayments data on file, last reported at $725000.0 in Q4 2020.

• Quarterly Long-Term Debt Repayments rose 190.0% year-over-year to $725000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $2.1 million (up 105.8% YoY) and the FY2020 annual result came in at $2.8 million, up 175.0% from the prior year.
• Long-Term Debt Repayments retreated to $725000.0 in Q4 2020, from $750000.0 in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $4.7 million in Q3 2018 to a low of $167000.0 in Q2 2019.
• A 5-year average of $706388.9 and a median of $268500.0 in 2016 frame the typical range for Long-Term Debt Repayments.
• Annual changes were most pronounced in 2018 — Long-Term Debt Repayments surged 2159.71% — and 2019, when it sank 92.85%.
• Tracing ERNAW's Long-Term Debt Repayments over 5 years: stood at $261000.0 in 2016, then plunged by 30.65% to $181000.0 in 2017, then surged by 95.58% to $354000.0 in 2018, then declined by 29.38% to $250000.0 in 2019, then surged by 190.0% to $725000.0 in 2020.
• The last three Long-Term Debt Repayments figures came in at $725000.0 (Q4 2020), $750000.0 (Q1 2020), and $250000.0 (Q4 2019), per Business Quant data.